Expert Interview
Discussing Menin Inhibitor Combination Data in Frontline AML from Syndax (Revumenib) and Kura Oncology/Kyowa Kirin (KOMZIFTI™ Ziftomenib).
Ticker(s): KURA, SNDXInstitution: University of Texas at Austin
- Deputy Director of the Livestrong Cancer Institutes at Dell Medical School and Vice Dean of research at University at Texas, Austin
- Manages 4 patients per month with T-ALL/LBL
- Carried out laboratory-based translational research throughout his career and focused on studying cancer stem cells, tumor cells with enhanced growth potential and their role in clinical oncology
- Expert's laboratory has also demonstrated that several pathways regulating normal stem cells, including those involved in embryonic development, are abnormally activated in cancer stem cells
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
